Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 1, 2007, Pages 403-412

  Hayakawa, Masahiko ^a   Kaizawa, Hiroyuki ^a   Kawaguchi, Ken ichi ^a   Ishikawa, Noriko ^a   Koizumi, Tomonobu ^a   Ohishi, Takahide ^a   Yamano, Mayumi ^a   Okada, Minoru ^a   Ohta, Mitsuaki ^a   Tsukamoto, Shin ichi ^a   Raynaud, Florence I ^b   Waterfield, Michael D ^c   Parker, Peter ^d   Workman, Paul ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Cancer treatment; Inhibitor; p110 ; PI3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 [1 [(4 FLUOROPHENYL)SULFONYL] 1H PYRAZOL 3 YL] 2 METHYLIMIDAZO[1,2 A]PYRIDINE; 6 BROMO 2 METHYL 3 [1 [(2 METHYL 5 NITROPHENYL)SULFONYL] 1H PYRAZOL 3 YL]IMIDAZO[1,2 A]PYRIDINE; 6 BROMO 3 [1 [(2 METHYL 5 NITROPHENYL)SULFONYL] 1H PYRAZOL 3 YL]IMIDAZO[1,2 A]PYRIDINE; 6 CHLORO 2 METHYL 3 [1 [(2 METHYL 5 NITROPHENYL)SULFONYL] 1H PYRAZOL 3 YL]IMIDAZO[1,2 A]PYRIDINE; 6 CHLORO 2 METHYL 3 [1 [(3 NITROPHENYL)SULFONYL] 1H PYRAZOL 3 YL]IMIDAZO[1,2 A]PYRIDINE; 6 CHLORO 2 METHYL 3 [1 [(4 NITROPHENYL)SULFONYL] 1H PYRAZOL 3 YL] 2 METHYLIMIDAZO[1,2 A]PYRIDINE; 6 CHLORO 3 [1 [(4 FLUOROPHENYL)SULFONYL] 1H PYRAZOL 3 YL] 2 METHYLIMIDAZO[1,2 A]PYRIDINE; 6 CHLORO 3 [2 [(2 METHYL 5 NITROPHENYL)SULFINYL] 1,3 THIAZOL 4 YL]IMIDAZO[1,2 A]PYRIDINE; 6 CHLORO 3 [2 [(2 METHYL 5 NITROPHENYL)SULFONYL] 1,3 THIAZOL 4 YL]IMIDAZO[1,2 A]PYRIDINE; 6 CHLORO 3 [2 [(2 METHYL 5 NITROPHENYL)THIOL] 1,3 THIAZOL 4 YL]IMIDAZO[1,2 A]PYRIDINE; [2 [[4 (6 CHLOROIMIDAZO[1,2 A]PYRIDIN 3 YL) 1,3 THIAZOL 2 YL]SULFINYL] 4 NITROPHENYL]METHANOL; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; SCINTILLATION; TUMOR GROWTH; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; INJECTIONS, INTRAPERITONEAL; ISOENZYMES; MICE; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33750953816     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.09.047     Document Type: Article

References (29)

1. Leevers S.J., Vanhaesebroeck B., and Waterfield M.D. Curr. Opin. Cell Biol. 11 (1999) 219-225
2. Lawlor M.A., and Alessi D.R. J. Cell Sci. 114 (2001) 2903-2910
3. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., and Waterfield M.D. Annu. Rev. Biochem. 70 (2001) 535-602
4. Cantley L.C. Science 296 (2002) 1655-1657
5. Hopkins K. Science 282 (1998) 1027-1030
6. Maehama T., and Dixon J.E. Trends Cell Biol. 9 (1999) 125
7. Simpson L., and Parsons R. Exp. Cell Res. 264 (2001) 29-41
8. Domin J., and Waterfield M.D. FEBS Lett. 410 (1997) 91-95
9. Vanhaesebroeck B., and Waterfield M.D. Exp. Cell Res. 253 (1999) 239-254
10. Vanhaesebroeck B., Leevers S.J., Panayatou G., and Waterfield M.D. Trends Biochem. Sci. 22 (1997)
11. Fruman D.A., Meyers R.E., and Cantley L.C. Annu. Rev. Biochem. 67 (1998) 481
12. Shayesteh L., Lu Y., Kuo W.-L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., and Gray J.W. Nat. Genet. 21 (1999) 99-102
13. Ma Y.-Y., Wei S.-J., Lin Y.-C., Lung J.-C., Chang T.-C., Whang-Peng J., Liu J.M., Yang D.-M., Yang W.K., and Schen C.-Y. Oncogene 19 (2000) 2739-2744
14. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. Science 304 (2004) 554
15. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., Cristiano B.E., Pearson R.B., and Phillips W.A. Cancer Res. 64 (2004) 7678-7681
16. Kang S., Bader A.G., and Vogt P.K. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 802-807
17. Parsons D.W., Wang T.-L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., and Velculescu V.E. Nature 436 (2005) 792
18. Schultz R.M., Merriman R.L., Andis S.L., Bonjouklian R., Grindey G.B., Rutherford P.G., Gallegos A., Massey K., and Powis G. Anticancer Res. 15 (1995) 1135-1139
19. Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.D., and Panayotou G. Mol. Cell. Biol. 16 (1996) 1722-1733
20. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. J. Biol. Chem. 269 (1994) 5241-5248
21. Ward S., Sotsios Y., Dowden J., Bruce I., and Finan P. Chem. Biol. 10 (2003) 207-213
22. Ward S.G., and Finan P. Curr. Opin. Pharmacol. 3 (2003) 426-434
23. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Okada M., Ohta M., Tsukamoto S., Parker P., Workman P., and Waterfield M. Bioorg. Med. Chem. 14 (2006) 6847-6858
24. van Leusen A.M., Siderius H., Hoogenboom B.E., and van Leusen D. Tetrahedron Lett. 13 (1972) 5337-5340
25. Pavri N.P., and Trudell M.L. J. Org. Chem. 62 (1997) 2649-2651
26. Petrillo G., Novi M., Garbarino G., and Dell'Erba C. Tetrahedron Lett. 26 (1985) 6365-6368
27. Covarrubias-Zuniga A., Diaz-Dominguez J., and Olguin-Uribe J.S. Synth. Commun. 31 (2001) 1373-1381
28. Podergajs S., Stanovnik B., and Tisler M. Synthesis (1984) 263-265
29. Starrett J.E., Montzka T.A., Crosswell A.R., and Cavanagh R.L. J. Med. Chem. 32 (1989) 2204-2210